Movement Alert｜PHARMARON Intraday Rise 3.88% in Regular Trading, Institutional Position Increases and Fund Investment Updates Support Sentiment

Market Focus11-10

On November 10, PHARMARON recorded an Intraday Rise of 3.88% in Regular Trading, trading at HK$30.3 with turnover of HK$8.30 million.

The move coincided with recent disclosures showing increased institutional positions and the company’s overseas fund investment progress. JPMorgan disclosed an off-exchange cash purchase of 771,700 shares on November 3 at an average price of about HK$26.01 per share, lifting its long position ratio to 17.19%. Separately, Morgan Stanley disclosed on November 4 that it increased shares subject to rehypothecation or disposal rights by 3.3245 million shares, raising its long position ratio to 6.05%; this was described as a non-open-market share interest arrangement rather than a direct secondary-market stock purchase.

Separately, the company said its wholly owned unit Pharmaron UK Limited signed subscription documents on November 6 to commit US$10 million to HJ Double Helix Fund L.P., aimed at leveraging specialist biotech investment and research capabilities to enhance its industry investment footprint.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156075670?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-10 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156075670","market":"hk","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Intraday Rise 3.88% in Regular Trading, Institutional Position Increases and Fund Investment Updates Support Sentiment","media":"Market Focus","content":"<p><p>On November 10, PHARMARON recorded an Intraday Rise of 3.88% in Regular Trading, trading at HK$30.3 with turnover of HK$8.30 million.</p><p>The move coincided with recent disclosures showing increased institutional positions and the company’s overseas fund investment progress. JPMorgan disclosed an off-exchange cash purchase of 771,700 shares on November 3 at an average price of about HK$26.01 per share, lifting its long position ratio to 17.19%. Separately, Morgan Stanley disclosed on November 4 that it increased shares subject to rehypothecation or disposal rights by 3.3245 million shares, raising its long position ratio to 6.05%; this was described as a non-open-market share interest arrangement rather than a direct secondary-market stock purchase.</p><p>Separately, the company said its wholly owned unit Pharmaron UK Limited signed subscription documents on November 6 to commit US$10 million to HJ Double Helix Fund L.P., aimed at leveraging specialist biotech investment and research capabilities to enhance its industry investment footprint.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Intraday Rise 3.88% in Regular Trading, Institutional Position Increases and Fund Investment Updates Support Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Intraday Rise 3.88% in Regular Trading, Institutional Position Increases and Fund Investment Updates Support Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-11-10 09:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On November 10, PHARMARON recorded an Intraday Rise of 3.88% in Regular Trading, trading at HK$30.3 with turnover of HK$8.30 million.</p><p>The move coincided with recent disclosures showing increased institutional positions and the company’s overseas fund investment progress. JPMorgan disclosed an off-exchange cash purchase of 771,700 shares on November 3 at an average price of about HK$26.01 per share, lifting its long position ratio to 17.19%. Separately, Morgan Stanley disclosed on November 4 that it increased shares subject to rehypothecation or disposal rights by 3.3245 million shares, raising its long position ratio to 6.05%; this was described as a non-open-market share interest arrangement rather than a direct secondary-market stock purchase.</p><p>Separately, the company said its wholly owned unit Pharmaron UK Limited signed subscription documents on November 6 to commit US$10 million to HJ Double Helix Fund L.P., aimed at leveraging specialist biotech investment and research capabilities to enhance its industry investment footprint.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1156075670","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156075670","pubTimestamp":1794274537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On November 10, PHARMARON recorded an Intraday Rise of 3.88% in Regular Trading, trading at HK$30.3 with turnover of HK$8.30 million.The move coincided with recent disclosures showing increased...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易盘中上涨3.88%，机构加仓和基金投资更新支撑人气","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On November 10, PHARMARON recorded an Intraday Rise of 3.88% in Regular Trading, trading at HK$30.3 with turnover of HK$8.30 million.The move coincided with recent disclosures showing increased institutional positions and the company’s overseas fund investment progress. JPMorgan disclosed an off-exchange cash purchase of 771,700 shares on November 3 at an average price of about HK$26.01 per share, lifting its long position ratio to 17.19%. Separately, Morgan Stanley disclosed on November 4 that it increased shares subject to rehypothecation or disposal rights by 3.3245 million shares, raising its long position ratio to 6.05%; this was described as a non-open-market share interest arrangement rather than a direct secondary-market stock purchase.Separately, the company said its wholly owned unit Pharmaron UK Limited signed subscription documents on November 6 to commit US$10 million to HJ Double Helix Fund L.P., aimed at leveraging specialist biotech investment and research capabilities to enhance its industry investment footprint.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156075670","isCrawlerRequest":true}